Literature DB >> 21317431

Full, shared and hybrid paediatric care for cystic fibrosis in South and Mid Wales.

Iolo Doull1, Hazel Evans.   

Abstract

BACKGROUND: Although care for children with cystic fibrosis (CF) is increasingly shared between CF centres and local CF clinics, the optimal model is unclear.
OBJECTIVES: The authors compared three models of care within a well established CF network: full centre care; local clinic based care with annual review by the CF centre; and hybrid care, where the child is usually reviewed at least three times a year by the specialist CF centre.
RESULTS: Of 199 children and young people with CF in South and Mid Wales, 77 were receiving full care, 102 shared care and 20 hybrid care. There were no significant differences in baseline characteristics, nutritional outcomes or use of chronic therapies. There was however a statistically significant difference between full, shared and hybrid care in mean forced expiratory volume in 1 s (FEV(1)) per cent predicted (89.2% vs 74.5% vs 88.9%; p=0.001).
CONCLUSIONS: These differences in pulmonary function are likely to reflect the model of care received, and may affect long term outcomes.

Entities:  

Mesh:

Year:  2011        PMID: 21317431     DOI: 10.1136/adc.2010.199380

Source DB:  PubMed          Journal:  Arch Dis Child        ISSN: 0003-9888            Impact factor:   3.791


  3 in total

Review 1.  Shared care--is it worth it for the patient?

Authors:  Iolo Doull
Journal:  J R Soc Med       Date:  2012-06       Impact factor: 5.344

2.  Comparing cystic fibrosis outcomes across the pond.

Authors:  David C Taylor-Robinson; Michael S Schechter; Rosalind L Smyth
Journal:  Thorax       Date:  2014-12-23       Impact factor: 9.139

3.  Do children with cystic fibrosis receiving outreach care have poorer clinical outcomes than those treated at a specialist cystic fibrosis centre?

Authors:  Heinrich C Weber; Philip F Robinson; Nicole Saxby; Sean A Beggs; Ingrid Els; Rodney I Ehrlich
Journal:  Aust J Rural Health       Date:  2016-11-17       Impact factor: 1.662

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.